Cann Group Ltd has released a press release.
Satipharm CBD products get green light from UK FSA
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cann
- Mildura facility practical completion & ODC permit granted
- Cann to begin recruitment for CBD phase 3 clinical trial
- Cann granted GMP licence & other regulatory updates
- Results of Share Purchase Plan offer
- Appendix 4E & Audited Financial Statements for FY21
Later from Cann
- Evaluation and option agreement with GSK Consumer Healthcare
- ODC manufacture permit granted for Mildura
- New funding arrangements with National Australia Bank
- Monthly Activities/Appendix 4C Cash Flow Report
- GMP manufacturing licence granted for Mildura
Follow Cann into a list and get an email when it puts out news.
Follow Cann